INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA
Instituto
Hospital de Sant Pau i Santa Tecla
Tarragona, EspañaPublicaciones en colaboración con investigadores/as de Hospital de Sant Pau i Santa Tecla (17)
2017
-
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial
The Lancet Oncology, Vol. 18, Núm. 2, pp. 241-250
-
Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group
British Journal of Haematology, Vol. 178, Núm. 5, pp. 699-708
2013
-
Characterization and prognostic implication of 17 chromosome abnormalities in myelodysplastic syndrome
Leukemia Research, Vol. 37, Núm. 7, pp. 769-776
2012
-
Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease
Haematologica, Vol. 97, Núm. 4, pp. 616-621
-
Chronic lymphocytic leukaemia with 17p deletion: A retrospective analysis of prognostic factors and therapy results
British Journal of Haematology, Vol. 157, Núm. 1, pp. 67-74
-
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: A randomized phase 3 PETHEMA/GEM study
Blood, Vol. 120, Núm. 8, pp. 1589-1596
2011
-
Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens
Blood, Vol. 117, Núm. 6, pp. 1799-1805
-
Observational prospective study of viral infections in children undergoing allogeneic hematopoietic cell transplantation: A 3-year GETMON experience
Bone Marrow Transplantation, Vol. 46, Núm. 1, pp. 119-124
2010
-
Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy
Haematologica, Vol. 95, Núm. 3, pp. 424-431
2009
-
Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis
Haematologica, Vol. 94, Núm. 9, pp. 1242-1249
-
Differentiation syndrome in patients with acute promyelocytic leukemia treated with all- trans retinoic acid and anthracycline chemotherapy: Characteristics, outcome, and prognostic factors
Blood, Vol. 113, Núm. 4, pp. 775-783
-
Imipenem/Cilastatin with or without Glycopeptide as Initial Antibiotic Therapy for Recipients of Autologous Stem Cell Transplantation: Results of a Spanish Multicenter Study
Biology of Blood and Marrow Transplantation, Vol. 15, Núm. 4, pp. 512-516
2008
-
Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin
Blood, Vol. 111, Núm. 7, pp. 3395-3402
-
Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: Long-term outcome of the LPA 99 multicenter study by the PETHEMA Group
Blood, Vol. 112, Núm. 8, pp. 3130-3134
2003
2001
-
Allogeneic transplantation of CD34+ -selected cells from peripheral blood in patients with myeloid malignancies in early phase: A case control comparison with unmodified peripheral blood tranplantation
Bone Marrow Transplantation, Vol. 28, Núm. 4, pp. 349-354
-
Fluoxetine in the prevention of depressive recurrences: A double-blind study
Journal of Clinical Psychopharmacology, Vol. 21, Núm. 4, pp. 417-424